405 Results for "

SRC

" in MedChemExpress (MCE) Product Catalog:
Products (405)

405 Results for "SRC" in MCE Product Catalog:

  • Targets Recommended:
  • Recombinant Proteins Recommended:
179
179 Publications Verification
Cat. No.: HY-10181A
CAS No.: 854001-07-3
Purity:  98.86%
Synonyms: BMS-354825 hydrochloride
Research Areas:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
loading...
    loading...
179
179 Publications Verification
Cat. No.: HY-10181B
CAS No.: 863127-77-9
Purity:  99.58%
Synonyms: BMS-354825 monohydrate
Research Areas:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
loading...
    loading...
179
179 Publications Verification
Cat. No.: HY-10181
CAS No.: 302962-49-8
Purity:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier .
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-13805
CAS No.: 172889-27-9
Purity:  98.34%
Synonyms: AGL 1879
Target:  

Src

Research Areas:  

Cancer

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-12047
CAS No.: 943319-70-8
Purity:  99.67%
Synonyms: AP24534
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-108766
CAS No.: 1114544-31-8
Purity:  99.76%
Synonyms: AP24534 hydrochloride
Research Areas:  

Infection Cancer

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-10234A
CAS No.: 893428-72-3
Purity:  99.24%
Synonyms: AZD0530 difumarate
Target:  

Src

Research Areas:  

Cancer

Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-10234
CAS No.: 379231-04-6
Purity:  99.92%
Synonyms: AZD0530
Target:  

Src Autophagy

Research Areas:  

Cancer

Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-10230
CAS No.: 120685-11-2
Purity:  99.91%
Synonyms: PKC412; CGP 41251
Research Areas:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-15176A
CAS No.: 1781882-65-2
Purity:  98.53%
Synonyms: RR82 hydrochloride
Pyridostatin (RR82) hydrochloride is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin hydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin hydrochloride targets the proto-oncogene Src. Pyridostatin hydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-15176B
CAS No.: 1472611-44-1
Purity:  99.54%
Synonyms: RR82 TFA
Pyridostatin (RR82) TFA is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin TFA also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin TFA interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin TFA exhibits antiproliferative and antiviral activities. Pyridostatin TFA can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-15176C
CAS No.: 2517456-88-9
Synonyms: RR82 trihydrochloride
Pyridostatin (RR82) trihydrochloride is a G-quadruplex (G4) inducer/stabilizer with a Kd of 490 nM. Pyridostatin trihydrochloride also acts as an inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 11.0 μM. Pyridostatin trihydrochloride interacts with G-quadruplex structures, regulates the expression of SRC and SUB1, and induces replication- and transcription-dependent DNA damage, growth arrest, and genomic instability. Pyridostatin trihydrochloride exhibits antiproliferative and antiviral activities. Pyridostatin trihydrochloride can be used in studies related to breast cancer, cervical cancer, and Zika virus infection .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-B0789
CAS No.: 330161-87-0
Target:  

Src FAK Akt

Research Areas:  

Cancer

SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-10158
CAS No.: 380843-75-4
Purity:  99.89%
Synonyms: SKI-606
Target:  

Src Bcr-Abl Autophagy

Research Areas:  

Cancer

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-10158A
CAS No.: 918639-08-4
Purity:  99.97%
Synonyms: SKI-606 hydrate
Target:  

Src Bcr-Abl

Research Areas:  

Cancer

Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-10321
CAS No.: 219580-11-7
Purity:  99.86%
Target:  

FGFR VEGFR Apoptosis

Research Areas:  

Cancer

PD173074 is a potent FGFR1 inhibitor with an IC50 of 25 nM and also inhibits VEGFR2 with an IC50 of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101053
CAS No.: 179248-59-0
Purity:  99.93%
Synonyms: SRC Kinase Inhibitor 1; SRC-l1
Target:  

Src

Research Areas:  

Cancer

Src Inhibitor 1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13804
CAS No.: 172889-26-8
Purity:  99.19%
Synonyms: AGL 1872; EI 275
Target:  

Src Apoptosis

Research Areas:  

Cancer

PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC50 of 5 and 6 nM for Lck and Fyn, respectively.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13024
CAS No.: 1020172-07-9
Purity:  99.91%
Synonyms: DCC-2036
Target:  

Bcr-Abl FLT3 Src Apoptosis

Research Areas:  

Cancer

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1 WT and Abl1 T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-12068
CAS No.: 1349796-36-6
Purity:  99.46%
Synonyms: XL-147 derivative 1
Target:  

PI3K

Research Areas:  

Cancer

PI3K-IN-1 (XL-147 derivative 1) is a potent inhibitor of PI3K. PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways .
loading...
    loading...